Cooley is advising FibroGen on its $167.7 million initial public offering. With a $1.04 billion valuation, this is the largest biotech IPO by market cap since 2002.

FibroGen is a biotechnology company focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer and other serious unmet medical needs. The company now trades on the Nasdaq Global Market under the symbol “FGEN.”

The Cooley corporate and securities team representing FibroGen is led by partner Glen Sato and includes partner Mike Tenta, associates Kevin Chen, Clark Chu, Taylor Young, Hannah Minkevitch and Eric Steiner.

Critical support for the offering was provided by associates Tracy Harrison and Rena Kaminsky (life sciences partnering); partner Michael Tuscan (patent counseling and prosecution); partner Christina Zhang and associate Hunter Qiu (international – Asia); partner Renee Deming and associate Sarah Dale (compensation and benefits); and partner Aaron Pomeroy (tax).